TG Therapeutics (TGTX) to Release Earnings on Wednesday

TG Therapeutics (NASDAQ:TGTX - Get Free Report) will likely be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect TG Therapeutics to post earnings of $0.09 per share and revenue of $100.67 million for the quarter.

TG Therapeutics Price Performance

Shares of TGTX stock traded down $0.06 during trading hours on Friday, hitting $30.88. 1,659,954 shares of the company's stock were exchanged, compared to its average volume of 1,631,928. The stock's 50-day moving average is $31.07 and its 200-day moving average is $27.78. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock has a market cap of $4.81 billion, a price-to-earnings ratio of -308.77 and a beta of 2.26. TG Therapeutics has a 52 week low of $12.90 and a 52 week high of $36.84.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the firm's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the transaction, the chief financial officer now directly owns 670,632 shares in the company, valued at $20,313,443.28. This trade represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TGTX. TD Cowen began coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a "buy" rating and a $50.00 target price on the stock. StockNews.com cut TG Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, January 31st. HC Wainwright restated a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a report on Wednesday, January 15th. The Goldman Sachs Group raised their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.